Compare Definium Therapeutics Inc. Common Shares (DFTX) vs Target Corporation (TGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Definium Therapeutics Inc. Common Shares vs Target Corporation — how do they compare? Definium Therapeutics Inc. Common Shares trades at $35.95 (market cap $4.59B), while Target Corporation trades at $154.8 (market cap $68.56B). The key difference: Target Corporation is far larger — about 14.9× Definium Therapeutics Inc. Common Shares's market cap, and Target Corporation pays a 3.07% dividend while Definium Therapeutics Inc. Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and Target Corporation for 137 Days on average.
| DFTX | TGT | |
|---|---|---|
Market Cap | $4.59B | $68.56B |
Volume | 2,103,937 | 4,507,338 |
Sector | Health | Consumer Staples |
52-Week High | $48.45 | $169.90 |
52-Week Low | $10.68 | $83.68 |
Typical Hold Time | 0 Days | 137 Days |
Enterprise Value | $3.55B | $81.84B |
Dividend Yield | — | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Target Corporation (TGT) trades at $150.96, down 2.18% today, with a bearish technical signal despite strong recent earnings beats. The company maintains solid fundamentals with $106.57B revenue, 4.08% net margin, and attractive valuation ratios including a P/E of 15.66. Recent price cuts on 2,000 items aim to capture holiday market share, while dividend payments continue reliably.
Target presents a mixed outlook with analyst consensus at $167.18 (11% upside) but technical weakness. The turnaround strategy shows promise with three consecutive earnings beats, though competitive pressures and margin compression remain key risks. Cash flow stability and dividend aristocrat status provide downside protection for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Definium Therapeutics Inc. Common Shares
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →
